Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease - Episode 6

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

, ,

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

EP. 1: Background on Graft-vs-Host Disease: Risk Factors and Prevention
EP. 2: Acute vs Chronic GVHD: Identification and Stratification
EP. 3: Frontline Treatment Options for Chronic GVHD
EP. 4: Defining Steroid-Refractory and Steroid-Dependent GVHD
EP. 5: Identifying and Managing Steroid-Refractory Chronic GVHD
Now Viewing
EP. 6: Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease
EP. 7: Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease
EP. 8: Mechanism of Action of Ruxolitinib
EP. 9: REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD
EP. 10: Chronic GVHD: Real-World Use of Ruxolitinib
EP. 11: Selecting Second-Line Therapy for Chronic GVHD
EP. 12: Chronic GVHD: Novel Treatment Approaches With Approved Agents
EP. 13: Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials
EP. 14: HSCT Approaches to Retain GVL While Preventing GVHD
EP. 15: Emerging Treatment Strategies for Chronic GVHD

Related Content:

Inside the Clinic: Updates in Diagnosis, Treatment, and Management of Chronic Graft-Versus-Host Disease Hematologic Oncology
Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL
Dr Daver on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)